GJGoljamal Jorjani

Goljamal Jorjani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Goljamal Jorjani has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence of rhabdomyolysis occurrence in psychoactive substances intoxication: a systematic review and meta-analysis

    by Alireza Amanollahi, Tannaz Babeveynezhad, Mohsen Sedighi, Shahin Shadnia, Sadaf Akbari, Mahbobeh Taheri, Mahboobeh Besharatpour, Goljamal Jorjani, Elham Salehian, Koorosh Etemad, et al.

    Rhabdomyolysis is a potentially life-threatening condition induced by diverse mechanisms including drugs and toxins. We aimed to investigate the incidence of rhabdomyolysis occurrence in intoxicated patients with psychoactive substances. In this review, three databases (PubMed, Scopus, Web of Science) and search engine (Google Scholar) were searched by various keywords. After the screening of retrieved documents, related data of included studies were extracted and analyzed with weighted mean difference (WMD) in random effect model. The highest incidence of rhabdomyolysis was observed in intoxication with heroin (57.2 [95% CI 22.6–91.8]), amphetamines (30.5 [95% CI 22.6–38.5]), and cocaine (26.6 [95% CI 11.1–42.1]). The pooled effect size for blood urea nitrogen (WMD = 8.78, p = 0.002), creatinine (WMD = 0.44, p < 0.001), and creatinine phosphokinase (WMD = 2590.9, p < 0.001) was high in patients with rhabdomyolysis compared to patients without rhabdomyolysis. Our results showed a high incidence of rhabdomyolysis induced by psychoactive substance intoxication in ICU patients when compared to total wards. Also, the incidence of rhabdomyolysis occurrence was high in ICU patients with heroin and amphetamine intoxication. Therefore, clinicians should anticipate this complication, monitor for rhabdomyolysis, and institute appropriate treatment protocols early in the patient’s clinical course.